Flag of the European Union EU Clinical Trials Register Help

Clinical trials for esophageal cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43873   clinical trials with a EudraCT protocol, of which   7293   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    202 result(s) found for: esophageal cancer. Displaying page 1 of 11.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-011174-15 Sponsor Protocol Number: 2700/2008 Start Date*: 2009-03-16
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: PRE-OPERATIVE CHEMO-RADIOTHERAPIC TREATMENT IN ESOPHAGEAL AND GASTRO-ESOPHAGEAL JUNCTION ADENOCARCINOMA
    Medical condition: ESOPHAGEAL AND GASTRO-ESOPHAGEAL JUNCTION ADENOCARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061882 LLT
    9.1 10030137 PT
    9.1 10066350 LLT
    9.1 10061882 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005787-58 Sponsor Protocol Number: eCaEP2021 Start Date*: 2021-05-12
    Sponsor Name:Michael Patrick
    Full Title: Endoscopic assisted Calcium electroporation in esophageal cancer – a safety study
    Medical condition: Esophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10015362 Esophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-002056-86 Sponsor Protocol Number: AIO-STO-0117 Start Date*: 2017-12-20
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: A multicenter open-label phase II trial to evaluate Nivolumab and Ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer
    Medical condition: advanced esophageal squamous cell cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055102 Oesophageal cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015362 Esophageal cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030151 Oesophageal cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015363 Esophageal cancer NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030152 Oesophageal cancer NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056267 Gastroesophageal cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062478 Esophageal cancer metastatic LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006647-31 Sponsor Protocol Number: ASSO OE-1 Start Date*: 2007-08-03
    Sponsor Name:The Austrian Society of Surgical Oncology (ACO-ASSO)
    Full Title: p53-Adjusted Neoadjuvant Chemotherapy for potentially resectable Oesophageal Cancer "pANCHO".
    Medical condition: Interaction between a predictive marker and response to induction chemotherapy in patients with potentially resectable esophageal cancer Predictive Marker Trial
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015362 Esophageal cancer LLT
    Population Age: Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020606-15 Sponsor Protocol Number: AIO-STO-0309 Start Date*: 2012-02-06
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced or metastatic esophageal squamous cell cancer
    Medical condition: Patients with nonresectable, advanced or metastatic esophageal squamous cell cancer (ESCC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015363 Esophageal cancer NOS LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062478 Esophageal cancer metastatic LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055102 Oesophageal cancer metastatic PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030152 Oesophageal cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) AT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002878-27 Sponsor Protocol Number: EECT2020 Start Date*: 2021-03-04
    Sponsor Name:Michael Patrick
    Full Title: Endoscopic electrochemotherapy in esophageal cancer – a phase II clinical trial
    Medical condition: Esophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10015362 Esophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-023427-18 Sponsor Protocol Number: LEOPARDII Start Date*: 2011-08-22
    Sponsor Name:University Hospital Schleswig-Holstein, Campus Luebeck
    Full Title: Definitive radiochemotherapy with 5-FU / cisplatin plus/minus cetuximab in unresectable locally advanced esophageal cancer: a phase II study
    Medical condition: Unresectable locally advanced esophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10015362 Esophageal cancer LLT
    19.1 100000004864 10030151 Oesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005556-10 Sponsor Protocol Number: CA209-577 Start Date*: 2016-05-24
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer
    Medical condition: Subjects with resected adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015362 Esophageal cancer LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030191 Oesophageal squamous cell carcinoma stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030190 Oesophageal squamous cell carcinoma stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030143 Oesophageal adenocarcinoma stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030144 Oesophageal adenocarcinoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing) ES (Ongoing) CZ (Trial now transitioned) GB (GB - no longer in EU/EEA) IE (Trial now transitioned) DE (Trial now transitioned) BE (Ongoing) DK (Trial now transitioned) NL (Ongoing) FR (Trial now transitioned) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002563-25 Sponsor Protocol Number: VEGF-RTX-2013 Start Date*: 2014-01-13
    Sponsor Name:VU University Medical Centre
    Full Title: Pilot study to determine the effect of fractionated radiotherapy on expression of pro-angiogenic factors in oeshophagus carcinoma
    Medical condition: Angiogenesis in esophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10015362 Esophageal cancer LLT
    20.0 100000004864 10030151 Oesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005051-42 Sponsor Protocol Number: PR016-CLN-pro003 Start Date*: 2008-03-20
    Sponsor Name:Protherics Salt Lake City, Inc
    Full Title: A randomized study of the efficacy and safety of OncoGel™ treatment as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation prior to surgery in subjects with locali...
    Medical condition: localized or loco-regional esophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015362 Esophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-003339-36 Sponsor Protocol Number: CA209473 Start Date*: 2016-05-12
    Sponsor Name:Ono Pharmaceutical Co., Ltd.
    Full Title: A Multicenter, Randomized, Open-label Study in Patients with esophageal Cancer refractory or intolerant to Combination Therapy with Fluoropyrimidine and Platinum-based Drugs
    Medical condition: Esophageal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10015362 Esophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001335-24 Sponsor Protocol Number: 141190 Start Date*: 2021-08-06
    Sponsor Name:Aarhus University
    Full Title: Thromboprophylaxis in Oesophageal Cancer Patients – A Randomized, Controlled Trial
    Medical condition: Thromboembolism in oesophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10030176 Oesophageal neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-013877-16 Sponsor Protocol Number: Number 1 Start Date*: 2009-10-30
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: Oesophageal squamous cell cancer: chemoradiotherapy versus chemotherapy and surgery - a feasibility study
    Medical condition: oesophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    12 10030151 Oesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000878-15 Sponsor Protocol Number: NL72398.041.19 Start Date*: 2020-04-15
    Sponsor Name:University Medical Center Utrecht
    Full Title: Sentinel node Navigation surgery in early esophageal Adenocarcinoma Patients with lymph node involvement: SNAP-IV study
    Medical condition: Esophageal adenocarcinoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003133-18 Sponsor Protocol Number: NL.58570.091.16 Start Date*: 2017-01-19
    Sponsor Name:radboudumc
    Full Title: Preoperative staging by combidex MRI in patients with resectable esophageal carcinoma, a feasibility study
    Medical condition: Detection of locoregional lymph node metastases in patients with resectable esophageal carcinoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021016-41 Sponsor Protocol Number: 10.05 Start Date*: 2011-01-14
    Sponsor Name:Odense University Hospital
    Full Title: Dose determination of Taxotere®, Eloxatin® and Xeloda® (TEX) in combination with Herpectin® as first line treatment to patients with HER2-positive non-resectable esophagus, cardia or gastric cancer
    Medical condition: Esophagus, cardiac or ventricular cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025899 Malignant neoplasm of esophagus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-000149-15 Sponsor Protocol Number: NEEDS Start Date*: 2020-04-22
    Sponsor Name:Karolinska University Hospital
    Full Title: NEoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial).
    Medical condition: Resectable locally advanced squamous cell carcinoma (SCC) of the esophagus
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10025899 Malignant neoplasm of esophagus LLT
    21.1 100000004864 10025901 Malignant neoplasm of esophagus, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-002031-92 Sponsor Protocol Number: EX0307 Start Date*: Information not available in EudraCT
    Sponsor Name:Otto-von-Guericke University
    Full Title: Proliferation and differentiation markers, involved in erosive and non-erosive reflux esophagitis, Barrett´s esophagus and esophageal adenocarcinoma.
    Medical condition: Dyspeptic Symptoms GERD (gastroesophageal reflux disease), NERD (non erosive reflux disease), ERD (erosive reflux disease), Barretts esophagus, Adeno-CA of the esophagus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017885 Gastrooesophageal reflux disease PT
    9.1 10004137 Barrett's oesophagus PT
    9.1 10001173 Adenocarcinoma of esophagus LLT
    9.1 10013949 Dyspeptic signs and symptoms HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001001-22 Sponsor Protocol Number: D910SC00001 Start Date*: 2021-03-30
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advance...
    Medical condition: Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10015366 Esophageal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Trial now transitioned) PL (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000935-42 Sponsor Protocol Number: IJB-GASTON-002-ARTEMIS-Eso Start Date*: 2017-04-20
    Sponsor Name:Institut Jules Bordet
    Full Title: Assessment of Metabolic and pathological Response to Treatment with Radio-chemotherapy (RCT) and Immunotherapy (ImT) before Surgery in locally advanced Esophageal and gastro-esophageal junction can...
    Medical condition: Adenocarcinomas of the esophagus or gastro-esophageal junction and squamous cell carcinoma of the esophagus.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061534 Oesophageal squamous cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 07 22:07:02 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA